Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + haemophilus influenzae type b conjugate vaccine
- Development stage
- Phase 3
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination vaccine contains **diphtheria toxoid**, **tetanus toxoid**, **acellular pertussis vaccine**, and **Haemophilus influenzae type b conjugate vaccine**. It provides active immunization against diphtheria, tetanus, pertussis (whooping cough), and invasive diseases caused by *Haemophilus influenzae* type b. These antigens stimulate an adaptive immune response by inducing production of antibodies specific to each pathogen. - **Diphtheria toxoid** and **tetanus toxoid** are inactivated toxins that induce antitoxin antibodies. - **Acellular pertussis vaccine** includes purified pertussis proteins that stimulate anti-pertussis immunity. - **Haemophilus influenzae type b conjugate vaccine** consists of Hib polysaccharide chemically linked to a protein carrier (commonly tetanus toxoid), enabling infants to mount a robust immune response against Hib. Primary indication is prevention of diphtheria, tetanus, pertussis, and Hib infections in infants and young children[3][5][1]. Approved and widely used combination brands include Pentacel (Sanofi Pasteur), Pediacel (Sanofi Pasteur), Infanrix IPV + Hib (GlaxoSmithKline), and Pentaxim (Sanofi Pasteur). TriHIBit (Sanofi Pasteur) has been discontinued[3][5][1].
- Brand names
- PentacelPediacelInfanrix IPV + HibPentaximTriHIBit
- Other names
- DTaP-Hib vaccinediphtheria and tetanus toxoids and acellular pertussis adsorbed with Haemophilus B conjugate vaccineDTaP-HibDTaP-IPV-Hib (if used in context of a five-in-one)diphtheria and tetanus toxoids and acellular pertussis adsorbed with Haemophilus influenzae type b conjugate vaccine
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + haemophilus influenzae type b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + haemophilus influenzae type b conjugate vaccine.